Mode
Text Size
Log in / Sign up
N/A Completed N=160 Randomized Single-blind Prevention

Evaluating Impact of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy

Parathyroid Adenoma · Thyroid Cancer · Hypercalcemia · Primary Hyperparathyroidism
Source: ClinicalTrials.gov NCT05022641 ↗
Enrolled (actual)
160
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcomePrimary: Average Number of Parathyroid Glands Identified — 2.7; 2.6 parathyroid glands per patient — p=.6

Summary

This study will see if the use of near infrared autofluorescence (NIRAF) detection with an FDA-cleared device 'Parathyroid Eye (PTeye)' for identifying parathyroid glands (PGs) during parathyroidectomy (PTx) procedures is better than a surgeon's detection alone. It compares risk-benefits and outcomes in PTx patients where NIRAF detection with PTeye for parathyroid identification is either used or not used. Parathyroidectomy - look at application of the technology to see if it assists during a parathyroidectomy.

Outcome Measures

OutcomeResultp-value
PRIMARY
Average Number of Parathyroid Glands Identified
2.7; 2.6 .6
SECONDARY
Parathyroid Hormone (PTH) Levels 5-14 Days After Surgery
23; 25.3 .65
SECONDARY
Appropriate Intraoperative Parathyroid Hormone Drop
45; 56; 35; 19 .02 sig
SECONDARY
Duration of Surgery
92.3; 88.8 0.6
SECONDARY
Number of Nights Spent in the Hospital After Parathyroidectomy
77; 76; 4; 3
SECONDARY
Number of Frozen Sections
49; 47; 32; 32 .6

Eligibility Criteria

Inclusion Criteria

  • Primary hyperparathyroidism who will be undergoing parathyroid surgery
  • Persistent primary hyperparathyroidism after having undergone a failed prior parathyroid surgery who will be undergoing repeat parathyroid surgery

Exclusion Criteria

  • Pregnant women (Those patients who could potentially will receive preoperative pregnancy testing, as is standard before general anesthesia. Any patients with positive pregnancy test results will not be included in the study.)
  • Patients with concurrent parathyroid and thyroid disease that require total thyroidectomy
  • Patients with secondary or tertiary hyperparathyroidism
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05022641). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search